Yasue Horiuchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7466781/publications.pdf

Version: 2024-02-01

257357 276775 1,929 65 24 41 citations h-index g-index papers 67 67 67 3065 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Role of glyoxalase 1 in methylglyoxal detoxification–the broad player of psychiatric disorders. Redox Biology, 2022, 49, 102222.	3.9	9
2	New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. International Journal of Molecular Sciences, 2022, 23, 975.	1.8	32
3	Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses. BMC Cancer, 2022, 22, 73.	1.1	5
4	Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. Japanese Journal of Clinical Oncology, 2022, 52, 599-608.	0.6	2
5	Exonic deletions in IMMP2L in schizophrenia with enhanced glycation stress subtype. PLoS ONE, 2022, 17, e0270506.	1.1	1
6	From population to neuron: exploring common mediators for metabolic problems and mental illnesses. Molecular Psychiatry, 2021, 26, 3931-3942.	4.1	16
7	Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients. Human Genetics, 2021, 140, 321-331.	1.8	16
8	Role of Tumor Mutation Burden Analysis in Detecting Lynch Syndrome in Precision Medicine: Analysis of 2,501 Japanese Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 166-174.	1.1	8
9	Cooperation of LIM domainâ€binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia. EMBO Molecular Medicine, 2021, 13, e12574.	3.3	2
10	Genomic profiling of multiple tissues in two patients with multiple endocrine neoplasia type 1. Biomedical Research, 2021, 42, 89-94.	0.3	0
11	Advanced glycation end products and cognitive impairment in schizophrenia. PLoS ONE, 2021, 16, e0251283.	1.1	6
12	Dysregulation of post-transcriptional modification by copy number variable microRNAs in schizophrenia with enhanced glycation stress. Translational Psychiatry, 2021, 11, 331.	2.4	7
13	Vitamin B6 deficiency hyperactivates the noradrenergic system, leading to social deficits and cognitive impairment. Translational Psychiatry, 2021, 11, 262.	2.4	16
14	Fingertip advanced glycation end products and psychotic symptoms among adolescents. NPJ Schizophrenia, 2021, 7, 37.	2.0	6
15	Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex. Redox Biology, 2021, 45, 102057.	3.9	12
16	LDB2 locus disruption on $4p16.1$ as a risk factor for schizophrenia and bipolar disorder. Human Genome Variation, 2020, 7, 31.	0.4	1
17	Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients. Cancer Medicine, 2019, 8, 5534-5543.	1.3	10
18	Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. BMC Cancer, 2019, 19, 1014.	1.1	3

#	Article	IF	CITATIONS
19	Fabry disease has been found by using of the tumor mutational burden analysis of 3000 Japanese cancer genomes using whole exome and targeted gene panel sequencing: Project Hightech Omics-based Patient Evaluation (Project HOPE). Molecular Genetics and Metabolism, 2019, 126, S154-S155.	0.5	O
20	Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry and Clinical Neurosciences, 2018, 72, 35-44.	1.0	40
21	Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules, 2018, 23, 1836.	1.7	28
22	A novel MLH1 intronic variant in a young Japanese patient with Lynch syndrome. Human Genome Variation, 2018, 5, 3.	0.4	1
23	A case of type 1 multiple endocrine neoplasia with esophageal stricture successfully treated with endoscopic balloon dilation and local steroid injection combined with surgical resection of gastrinomas. BMC Gastroenterology, 2017, 17, 37.	0.8	4
24	Germline and somatic genetic changes in multicentric tumors obtained from a patient with multiple endocrine neoplasia type 1. Human Genome Variation, 2017, 4, 17013.	0.4	1
25	Valley of death: A proposal to build a "translational bridge―for the next generation. Neuroscience Research, 2017, 115, 1-4.	1.0	33
26	Identification of an argpyrimidine-modified protein in human red blood cells from schizophrenic patients: A possible biomarker for diseases involving carbonyl stress. Biochemical and Biophysical Research Communications, 2017, 493, 573-577.	1.0	15
27	The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. Biochemical and Biophysical Research Communications, 2016, 479, 447-452.	1.0	14
28	Molecular signatures associated with cognitive deficits in schizophrenia: a study of biopsied olfactory neural epithelium. Translational Psychiatry, 2016, 6, e915-e915.	2.4	30
29	Determination of methylglyoxal in human blood plasma using fluorescence high performance liquid chromatography after derivatization with 1,2-diamino-4,5-methylenedioxybenzene. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1029-1030, 102-105.	1.2	24
30	Prevalence of low-penetrant germline <i>TP53</i> D49H mutation in Japanese cancer patients . Biomedical Research, 2016, 37, 259-264.	0.3	8
31	Characterization of modified proteins in plasma from a subtype of schizophrenia based on carbonyl stress: Protein carbonyl is a possible biomarker of psychiatric disorders. Biochemical and Biophysical Research Communications, 2015, 467, 361-366.	1.0	14
32	Clinical Utility of Neuronal Cells Directly Converted from Fibroblasts of Patients for Neuropsychiatric Disorders: Studies of Lysosomal Storage Diseases and Channelopathy. Current Molecular Medicine, 2015, 15, 138-145.	0.6	14
33	Carbonyl stress and schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 655-665.	1.0	29
34	<scp>NrCAM</scp> â€regulating neural systems and addictionâ€related behaviors. Addiction Biology, 2014, 19, 343-353.	1.4	29
35	Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: Utility and limitation of the surrogate tissues in research for brain disorders. Neuroscience Research, 2013, 77, 247-250.	1.0	51
36	DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics Journal, 2013, 13, 27-34.	0.9	38

#	Article	IF	CITATIONS
37	Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17552-17557.	3.3	65
38	Experimental Evidence for the Involvement of PDLIM5 in Mood Disorders in Hetero Knockout Mice. PLoS ONE, 2013, 8, e59320.	1.1	18
39	Association of SNPs linked to increased expression of SLC1A1 with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 30-37.	1.1	25
40	Generation of Induced Pluripotent Stem Cells from Human Nasal Epithelial Cells Using a Sendai Virus Vector. PLoS ONE, 2012, 7, e42855.	1.1	46
41	Functional polymorphism in the <i>GPR55</i> gene is associated with anorexia nervosa. Synapse, 2011, 65, 103-108.	0.6	36
42	A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse, 2010, 64, 92-96.	0.6	57
43	Association of the HSPG2 Gene with Neuroleptic-Induced Tardive Dyskinesia. Neuropsychopharmacology, 2010, 35, 1155-1164.	2.8	57
44	Supportive Evidence for Reduced Expression of GNB1L in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 756-765.	2.3	23
45	Generation of induced pluripotent stem cells from patients with schizophrenia. Neuroscience Research, 2010, 68, e314.	1.0	0
46	Brain Cannabinoid CB2 Receptor in Schizophrenia. Biological Psychiatry, 2010, 67, 974-982.	0.7	163
47	Replication study of association between ADCYAP1 gene polymorphisms and schizophrenia. Psychiatric Genetics, 2010, 20, 123-125.	0.6	15
48	Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Human Molecular Genetics, 2009, 18, 2483-2494.	1.4	103
49	Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 392-396.	1.1	20
50	A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophrenia Research, 2008, 101, 9-16.	1.1	59
51	Association of polymorphisms in the haplotype block spanning the alternatively spliced exons of the NTNG1 gene at 1p13.3 with schizophrenia in Japanese populations. Neuroscience Letters, 2008, 435, 194-197.	1.0	37
52	Replication study for associations between polymorphisms in the CLDN5 and DGCR2 genes in the 22q11 deletion syndrome region and schizophrenia. Psychiatric Genetics, 2008, 18, 255-256.	0.6	11
53	Pathway-based association analysis of genome-wide screening data suggest that genes associated with the \hat{I}^3 -aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenetics and Genomics, 2008, 18, 317-323.	0.7	95
54	Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics Journal, 2007, 7, 380-385.	0.9	119

#	Article	lF	CITATIONS
55	Failure to confirm the association between the FEZ1 gene and schizophrenia in a Japanese population. Neuroscience Letters, 2007, 417, 326-329.	1.0	16
56	PICK1 is not a susceptibility gene for schizophrenia in a Japanese population: Association study in a large case–control population. Neuroscience Research, 2007, 58, 145-148.	1.0	13
57	RGS4 is not a susceptibility gene for schizophrenia in Japanese: Association study in a large case-control population. Schizophrenia Research, 2007, 89, 161-164.	1.1	30
58	Support for association of the PPP3CC gene with schizophrenia. Molecular Psychiatry, 2007, 12, 891-893.	4.1	38
59	A Polymorphism in the PDLIM5 Gene Associated with Gene Expression and Schizophrenia. Biological Psychiatry, 2006, 59, 434-439.	0.7	37
60	Monoallelic and Unequal Allelic Expression of the HTR2A Gene in Human Brain and Peripheral Lymphocytes. Biological Psychiatry, 2006, 60, 1331-1335.	0.7	36
61	A novel susceptibility locus for moyamoya disease on chromosome 8q23. Journal of Human Genetics, 2004, 49, 278-281.	1.1	187
62	Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders. Biological Psychiatry, 2004, 55, 40-45.	0.7	40
63	Failure to find causal mutations in the GABAA-receptor \hat{I}^3 2 subunit (GABRG2) gene in Japanese febrile seizure patients. Neuroscience Letters, 2003, 343, 117-120.	1.0	25
64	A 58-kDa Shc Protein Is Present inXenopusEggs and Is Phosphorylated on Tyrosine Residues upon Egg Activation. Biochemical and Biophysical Research Communications, 1999, 258, 265-270.	1.0	17
65	Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Psychiatry, 0, 13, .	1.3	14